Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.
Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.
In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.
The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”
News of the hires comes weeks after Schrödinger pulled in more cash to fund its evolution into a biotech with an internal pipeline.
Comet Therapeutics unveiled itself with $28.5 million in series A financing and biopharma veteran David De Graaf at the helm.
Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.
Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.
Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.
The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding.
